Mapi Pharma to Host Virtual KOL Event to Discuss Glatiramer Acetate Once a Month Depot for Primary Progressive Multiple Sclerosis, on March 3, 2026
MWN-AI** Summary
Mapi Pharma Ltd., a biopharmaceutical company specializing in long-acting injectable treatments, will host a virtual key opinion leader (KOL) event on March 3, 2026, at 11:00 AM ET. The event will highlight Mapi's innovative Glatiramer Acetate Depot (GA Depot), a once-monthly injection designed for patients with Multiple Sclerosis (MS), specifically targeting Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Forms of Multiple Sclerosis (RMS).
Leading the discussions are esteemed experts in neurology: Dr. Aaron Miller from Mount Sinai and Dr. Carlo S. Tornatore from MedStar Georgetown University Hospital. They will address the existing treatment landscape and unmet needs within the MS community, as well as the efficacy of Mapi's depot technology. Adding to this, Shai Rubnov, Mapi's VP of R&D, will unveil insights about the company's product pipeline and approval process, while Mapi’s Chairman and CEO, Ehud Marom, will cover the company's financial outlook and follow up with a Q&A session.
The GA Depot is in advanced clinical trials, with a global Phase III study for PPMS set to commence, spurred by positive Phase II results showcased at the ACTRIMS Forum 2026. The clinical trial displayed a high rate of disability progression-free survival among participants, underscoring the potential of GA Depot in managing MS.
Mapi Pharma's strategic focus is on high-value life cycle management products and complex active pharmaceutical ingredients, with a commitment to expanding its portfolio in areas such as schizophrenia and diabetes. For registration details and further inquiries, interested parties can visit Mapi's website or contact their corporate development team.
MWN-AI** Analysis
As Mapi Pharma prepares to host a critical virtual KOL event on March 3, 2026, it's essential for potential investors and stakeholders to analyze the implications of this gathering on the company's market positioning. The event focuses on the promising Glatiramer Acetate Depot (GA Depot) for treating Primary Progressive Multiple Sclerosis (PPMS), which could address significant unmet needs within the MS treatment landscape.
Mapi Pharma's GA Depot has generated positive clinical trial results, particularly from the Phase II study, which demonstrated a remarkable 96.6% disability progression-free rate over 12 weeks. Such efficacy is likely to resonate well with KOLs, which may enhance the drug's credibility and future adoption once it progresses through the regulatory landscape.
Key opinion leaders like Dr. Aaron Miller and Dr. Carlo Tornatore participating in the event will provide critical insights into the treatment landscape, aiding investors in understanding the competitive advantages and potential market share for GA Depot. Their previous experience and accolades in the field suggest that their endorsements could catalyze interest from both the medical community and financial analysts.
Moreover, the global Phase III study commencement and ongoing discussions around commercial opportunities signal Mapi's aggressive strategy to capitalize on the growing need for innovative MS treatments. As the drug's profile is bolstered by a strong management team led by CEO Ehud Marom and VP R&D Shai Rubnov, confidence in Mapi's pipeline is poised to strengthen.
Investors should carefully monitor Mapi Pharma's developments leading up to and following the KOL event for potential price movements and shifts in market sentiment. Engaging with the data emerging from this event could provide actionable insights, underscoring Mapi Pharma as a potentially lucrative investment in the biopharmaceutical landscape. However, investors are advised to remain cautious given the inherent risks in clinical-stage companies navigating complex regulatory environments.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NESS ZIONA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, March 3, 2026 at 11:00 AM ET.
The event will feature presentations by Aaron Miller, MD (Corinne Dickinson Center for Multiple Sclerosis, Icahn School of Medicine, Mount Sinai) and Carlo S. Tornatore, MD (MedStar Health, MedStar Georgetown University Hospital), who will discuss the unmet needs and current treatment landscape for Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Forms of Multiple Sclerosis (RMS) based on Mapi’s Depot technology and IP. Shai Rubnov PhD, Mapi’s VP R&D will discuss the Mapi’s Depot technologies, product pipeline and their approval process and Ehud Marom, Mapi’s Chairman and CEO who will discuss the Company’s financial aspects and respond to questions. To register, click here.
Mapi’s Glatiramer Acetate Depot (GA Depot) is a once-monthly injection for the treatment of patients with multiple sclerosis. GA Depot is currently the subject of clinical studies for both relapsing forms of MS (RMS). The product is in a final review process in Germany and starting a global Phase III study for PPMS. Company management will review results from the successful multi-center Phase II clinical trial of GA Depot for PPMS with support from the excellent Phase III data from the RMS study. The recent PPMS results were presented at the ACTRIMS Forum 2026. Management will discuss next registration steps and commercial opportunities for both indications and unmet clinical needs.
A live question and answer session will follow the formal presentations.
About Aaron Miller, MD
Aaron Miller, MD is the Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis and a Professor of Neurology at the Icahn School of Medicine at Mount Sinai. He also serves as Vice-Chair for Education in the Department of Neurology. For 23 years prior to becoming Medical Director, he headed the Division of Neurology at Maimonides Medical Center in Brooklyn, New York, where he also served as director of the Multiple Sclerosis Care Center. Dr. Miller served as Chief Medical Officer and Chairman of the Medical Advisory Board of the National Multiple Sclerosis Society (NMSS) from October 2002-2009 and is the immediate past president of the National Medical Advisory Board. He also served as the Chairman of the Clinical Advisory Committee of the New York City Chapter of the NMSS from 1991-2004. He formerly served as the Chairman of the Professional Education Committee of the NMSS and is a past president of the Consortium of MS Centers. He was a member of the National Board of the NMSS from 2002-2017. Dr. Miller received the Hope Award from the National MS Society in 2021. He was also the first Chairman of the multiple sclerosis section of the American Academy of Neurology and has participated in numerous clinical trials of new treatments for multiple sclerosis. Dr. Miller is also very active with the American Academy of Neurology for which he served as Editor of Continuum, their bi-monthly continuing education publication from 2003-2012 and as Editor of Continuum Audio from 2012-2021. He was Secretary of the AAN Board (2013-2017) and was also a member of the Board from 2009-2013. From 1997-2003, he served as Co-chairman of the Education Committee and Chairman of the Annual Meeting Subcommittee.
About Carlo S. Tornatore, MD
Carlo S. Tornatore, MD is the Regional Chief of Neurology for MedStar Health and Chairman and Neurologist-in-Chief in the Department of Neurology at MedStar Georgetown University Hospital. He is also the Executive Director of the Multiple Sclerosis Patient Centered Specialty Practice MedStar Georgetown and Professor and Chairman in the Department of Neurology at Georgetown University Medical Center. Dr. Tornatore received his undergraduate degree in neurobiology from Cornell University and then attended Georgetown University School of Medicine where he received his medical degree. Following a Neurology Residency at Georgetown University Hospital, he was a post-doctoral fellow at the National Institute of Neurologic Disorders and Stroke at the National Institutes of Health. Dr. Tornatore has published extensively in the areas of neuroimmunology, neurovirology and Multiple Sclerosis and is currently involved in over 15 clinical trials for the treatment of Multiple Sclerosis. He has won multiple awards in the areas of medical student teaching, patient care and scholarly research.
About GA Depot Phase II Study Results
This was an open-label Phase IIa clinical trial that enrolled 30 patients with PPMS, treated with 25 mg (n = 10) or 40 mg (n = 20) IM GA Depot for up to 3 years. The results showed that overall disability remained stable over time, with mean EDSS scores improving slightly from 5.1 at baseline to 4.5 at three years. All patients except one did not experience confirmed disability progression (CDP) over 12 weeks, resulting in a disability progression free rate of 96.6%. Most patients also maintained stable physical function, with 89.7% remaining stable on the 9-Hole Peg Test and 79.3% on the Timed 25-Foot Walk. Sixty nine percent of patients showed no evidence of progression (NEP), with similar rates observed in both dose groups.
Treatment with GA Depot was generally well tolerated. Most adverse events (81.6%) were mild (most common were injection site reactions, asthenia, fever). AEs and ISRs rates were numerically lower with 25 mg than with 40 mg. No unexpected AEs were reported.
About Mapi Pharma
Mapi Pharma (Mapi) is a clinical stage pharmaceutical company, engaged in development of high barrier-to-entry and high added-value life cycle management (“LCM”) products and AB Rated Depot injectable products that target large markets that include complex active pharmaceutical ingredients (“APIs”) and formulations. Mapi’s lead product is GA Depot which is partnered with Viatris (NASDAQ: VTRS) in an agreement under which Viatris was granted an exclusive license to commercialize the GA Depot injection product for Relapsing Forms of Multiple Sclerosis (RMS). Following successful Phase 3 results GA Depot is currently under FDA & EU review. Mapi is developing depot long-acting injections for anti-psychotic and diabetes medical indications. The Company is also marketing its own generic versions of Fingolimod (Gilenya®) and Apremilast (Otezla®) in specific geographic markets. Mapi’s portfolio also includes a leading development of Depot drugs for Schizophrenia, GLP-1 for diabetes, weight loss, with innovative intellectual property. Mapi is built on strong chemical and pharmaceutical R&D and clinical development capabilities and a deep understanding of the global market and of regulatory needs. Mapi is a global company with an API production and aseptic depot manufacturing and a Fill & Finish for injectable Finished Dosage Forms. Mapi has strong IP positions, numerous granted patent applications for APIs and formulations. For more information, please visit www.mapi-pharma.com
Contacts:
Alex Mogle
Vice President, Corporate Development
Mapi Pharma
+972 52 6080297
alex@mapi-pharma.com
Brian Ritchie
Managing Director
LifeSci Advisors, LLC
britchie@lifesciadvisors.com
FAQ**
How is Mapi Pharma's collaboration with Viatris Inc. (NASDAQ: VTRS) expected to impact the market introduction and commercialization of the GA Depot for Relapsing Forms of Multiple Sclerosis?
What are the strategic implications of Mapi's ongoing clinical studies for the GA Depot and further development in partnership with Viatris Inc. (VTRS)?
Given the positive Phase II results for GA Depot, how does Mapi Pharma plan to leverage its relationship with Viatris Inc. (VTRS) in the global Phase III study for Primary Progressive Multiple Sclerosis?
What are Mapi Pharma’s next steps with regulatory agencies, particularly in relation to Ga Depot’s approval with the support of Viatris Inc. (NASDAQ: VTRS) after the successful Phase III results?
**MWN-AI FAQ is based on asking OpenAI questions about Viatris Inc. (NASDAQ: VTRS).
NASDAQ: VTRS
VTRS Trading
3.0% G/L:
$14.405 Last:
2,636,674 Volume:
$14.17 Open:
